OCALA, Fla., March 26, 2024to discuss the Company's Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM's leadership team, Chief Executive Officer Thomas K. Equels and Scientific Officer Christopher McAleer, PhD. Interested participants and investors may access the conference call by dialingwill be accessible on the Eventspage of the Investorssection of the Company's website, aimimmuno.com, and will be archived for 90 days following the live event.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.comand connect with the Company on X, LinkedIn, and Facebook.
